EP Patent

EP2399604A1 — Novel antibody formulation

Assigned to F Hoffmann La Roche AG · Expires 2011-12-28 · 14y expired

What this patent protects

The present invention relates to a pharmaceutical liquid formulation of an antibody against human OX40L, a process for the preparation and uses of the formulation.

USPTO Abstract

The present invention relates to a pharmaceutical liquid formulation of an antibody against human OX40L, a process for the preparation and uses of the formulation.

Drugs covered by this patent

Patent Metadata

Patent number
EP2399604A1
Jurisdiction
EP
Classification
—
Expires
2011-12-28
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.